Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
Primary Purpose
Growth Disorders, Malnutrition, Fetal, Stunting
Status
Recruiting
Phase
Not Applicable
Locations
Ecuador
Study Type
Interventional
Intervention
Evolutionary Nutrition Package
Sponsored by
About this trial
This is an interventional prevention trial for Growth Disorders
Eligibility Criteria
Inclusion Criteria:
- healthy
- in their first trimester
- carrying a singleton pregnancy
Exclusion Criteria:
- less than 18 years of age
- have a chronic health condition (HIV, TB, epilepsy, etc.)
- have a multiple pregnancy (twins, triplets, etc.)
- intend to move away from the study area
- have known allergies to eggs or fish
- have a blood pressure greater than 160/100
Sites / Locations
- Universidad San Francisco de QuitoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Experimental Group
Control Group
Arm Description
Receives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)]
Receives standard-of-care, iron-folic acid and calcium supplements.
Outcomes
Primary Outcome Measures
Length-for-age Z (LAZ)
LAZ is a measure of stunting, whether a child is the appropriate length/height for their age
Plasma concentrations of Docosahexaenoic acid (DHA)
Plasma concentration of DHA measured in µg/mL
Plasma concentrations of Linoleic acid (LA)
Plasma concentration of LA measured in µg/mL
Plasma concentrations of α-Linoleic acid (ALA)
Plasma concentration of ALA measured in µg/mL
Plasma concentrations of Betaine
Plasma concentration of Betaine measured in µg/mL
Plasma concentrations of Methionine
Plasma concentration of Methionine measured in µg/mL
Plasma Concentration of Choline
Plasma concentration of Choline measured in µg/mL
Plasma Concentration of Iron (Fe)
Plasma concentration of Iron (Fe) measured in mg/mL
Plasma Concentration of Zinc (Zn)
Plasma concentration of Zinc (Zn) measured in mg/mL
Plasma Concentration of Selenium (Se)
Plasma concentration of Selenium (Se) measured in mg/mL
Brain structure development--Gangliothalamic ovoid (GTO) volume
GTO volume measured in cm3
Brain structure development--Gangliothalamic ovoid (GTO) diameter
GTO diameter measured in cm
Brain structure development--Gangliothalamic ovoid (GTO) craniocaudal
GTO craniocaudal measured in cm
Brain structure development-- thalamic diameter
Thalamic diameter in cm
Secondary Outcome Measures
Maternal Morbidity
Rate of morbidities common during pregnancy including anemia, urinary tract infections, hypertension, gestational diabetes, respiratory infections, and hyperemesis gravidarum.
Full Information
NCT ID
NCT05242224
First Posted
June 28, 2019
Last Updated
February 6, 2022
Sponsor
Washington University School of Medicine
Collaborators
St. Louis Children's Hospital, St. Louis University, Children's Discovery Institute, Universidad San Francisco de Quito
1. Study Identification
Unique Protocol Identification Number
NCT05242224
Brief Title
Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
Official Title
Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 5, 2022 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
St. Louis Children's Hospital, St. Louis University, Children's Discovery Institute, Universidad San Francisco de Quito
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. This study will examine an evolutionary nutrition intervention during pregnancy derived from diets consumed for 99.9% of hominin history when bodies and brains were healthier. A pilot clinical trial will be conducted in the central highlands of Ecuador to compare fetal and newborn outcomes among women randomized to: 1) evolutionary nutrition package (high quality diet plus nutrition messaging); and 2) control (standard-of care supplements). Ultrasound brain measures, nutrition and morbidity data, and blood metabolomics will be assessed at 21 weeks gestational age, 37 weeks gestational stage, and postpartum. This pilot study uniquely combines the expertise of multiple disciplines - public health nutrition, radiology, neuroscience, and metabolomics - to examine the potential for improved nutrition on early growth and brain development with vital public health implications.
Detailed Description
The pilot trial will be conducted in the highlands of Ecuador in a mixed indigenous and non-indigenous population of pregnant women. Nationally, the stunting prevalence among young children is 25.3%, but large disparities within the country especially indigenous communities where stunting prevalence is nearly double, 42.3% (Freire et al., 2014). Incidence of low birthweight (8%) also varies by population in Ecuador, and may represent in utero growth restriction (IUGR) and other harmful exposures during pregnany (UNICEF 2012). While a large proportion of women have at least one antenatal care visit (84%), Only 58% of women in Ecuador meet the the WHO recommended 4+ antenatal care visits. This pilot project will leverage learnings from the Lulun Project and a previous antenatal health study (Gallegos et al. 2017) to design a social marketing campaign that encourages participation and high compliance. For this pilot RCT, the investigators will recruit pregnant women accessing antenatal care from Centro de Salud El Quinche in Pichincha province. Our target population will include those from poor households in particular (who access free public health services) with higher risks for IUGR and undernutrition during pregnancy.
The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes. In order to adapt the food groups to the Ecuador context, the investgators first developed a list of foods appropriate for the Ecuador context within each food group (Table 1). The food list draws on evidence from the Ministry of Health in Ecuador and USFQ for commonly consumed foods, notably among indigneous populations (Gallegos et al. 2010). Criteria for the full list of foods were the following: culturally appropriate; economically affordable and accessible; and environmentally sustainable. As was the experience with eggs in the Lulun Project, application of these criteria better ensure translation of findings within communities in the future.
Pregnant women will be recruited during first trimester of pregnancy and randomized to intervention group (EN plate + nutrition messaging + standard of care supplements) or control group (standard of care supplements). The intervention period will occur during second and third trimesters. Food supplies sufficient for one EN plate per day for 7 days will be delivered to pregnant women on a weekly basis. Under the supervision of the nutrition-trained field director, foods from each food group in pre-specified nutrient proportions will be secured from local food producers. Consideration will be given to including foods that do not require refrigeration over a one-week period. Careful documentation will be made of the foods contained in the weekly box in order to calculate exact quantity of nutrients provided. Due to concerns about food sharing that were evident in our qualitative research findings, additional food supplies will be provided for other household members in a separate container. Suggested menus and recipes will be provided with each delivery depending on the included foods.
Nutrition messages, developed in tandem with the social marketing campaign described below, will emphasize the importance of the food provisions for the participating pregnant women, but communicate the value of the EN plate for all household members. Messaging each week will reinforce the importance of eliminating ultraprocessed foods from the diet and reducing rice consumption. The absence of ultra processed foods is integral to our hypothesized effect and critical for confronting the dual burden of over- and under-nutrition in Ecuador (Freire et al. 2014). During each weekly food delivery visit, data will be collected on adherence and morbidities.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Growth Disorders, Malnutrition, Fetal, Stunting, Development; Delayed, Malnutrition, Nutrition Disorder, Fetal, Maternal Nutritional Disorders Affecting Fetus or Newborn
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental Group
Arm Type
Experimental
Arm Description
Receives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)]
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Receives standard-of-care, iron-folic acid and calcium supplements.
Intervention Type
Other
Intervention Name(s)
Evolutionary Nutrition Package
Intervention Description
The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
Primary Outcome Measure Information:
Title
Length-for-age Z (LAZ)
Description
LAZ is a measure of stunting, whether a child is the appropriate length/height for their age
Time Frame
6 months
Title
Plasma concentrations of Docosahexaenoic acid (DHA)
Description
Plasma concentration of DHA measured in µg/mL
Time Frame
6 months
Title
Plasma concentrations of Linoleic acid (LA)
Description
Plasma concentration of LA measured in µg/mL
Time Frame
6 months
Title
Plasma concentrations of α-Linoleic acid (ALA)
Description
Plasma concentration of ALA measured in µg/mL
Time Frame
6 months
Title
Plasma concentrations of Betaine
Description
Plasma concentration of Betaine measured in µg/mL
Time Frame
6 months
Title
Plasma concentrations of Methionine
Description
Plasma concentration of Methionine measured in µg/mL
Time Frame
6 months
Title
Plasma Concentration of Choline
Description
Plasma concentration of Choline measured in µg/mL
Time Frame
6 months
Title
Plasma Concentration of Iron (Fe)
Description
Plasma concentration of Iron (Fe) measured in mg/mL
Time Frame
6 months
Title
Plasma Concentration of Zinc (Zn)
Description
Plasma concentration of Zinc (Zn) measured in mg/mL
Time Frame
6 months
Title
Plasma Concentration of Selenium (Se)
Description
Plasma concentration of Selenium (Se) measured in mg/mL
Time Frame
6 months
Title
Brain structure development--Gangliothalamic ovoid (GTO) volume
Description
GTO volume measured in cm3
Time Frame
4 months
Title
Brain structure development--Gangliothalamic ovoid (GTO) diameter
Description
GTO diameter measured in cm
Time Frame
4 months
Title
Brain structure development--Gangliothalamic ovoid (GTO) craniocaudal
Description
GTO craniocaudal measured in cm
Time Frame
4 months
Title
Brain structure development-- thalamic diameter
Description
Thalamic diameter in cm
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Maternal Morbidity
Description
Rate of morbidities common during pregnancy including anemia, urinary tract infections, hypertension, gestational diabetes, respiratory infections, and hyperemesis gravidarum.
Time Frame
6 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy
in their first trimester
carrying a singleton pregnancy
Exclusion Criteria:
less than 18 years of age
have a chronic health condition (HIV, TB, epilepsy, etc.)
have a multiple pregnancy (twins, triplets, etc.)
intend to move away from the study area
have known allergies to eggs or fish
have a blood pressure greater than 160/100
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lora Iannotti, PhD
Phone
314-935-4396
Email
liannotti@wustl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa Chapnick, RD MS MPH
Phone
314-935-6483
Email
mchapnick@wustl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Waters, PhD
Organizational Affiliation
Universidad San Francisco de Quito
Official's Role
Study Director
Facility Information:
Facility Name
Universidad San Francisco de Quito
City
Quito
State/Province
Pichincha
ZIP/Postal Code
170901
Country
Ecuador
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Waters, PhD
Email
wwaters@usfq.edu.ec
12. IPD Sharing Statement
Learn more about this trial
Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
We'll reach out to this number within 24 hrs